Level Four Advisory Services LLC Acquires 3,602 Shares of Johnson & Johnson (NYSE:JNJ)

Level Four Advisory Services LLC raised its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 8.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 44,358 shares of the company’s stock after acquiring an additional 3,602 shares during the quarter. Level Four Advisory Services LLC’s holdings in Johnson & Johnson were worth $6,239,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently bought and sold shares of JNJ. Fulcrum Equity Management grew its position in Johnson & Johnson by 4.2% in the 2nd quarter. Fulcrum Equity Management now owns 3,657 shares of the company’s stock valued at $514,000 after acquiring an additional 149 shares in the last quarter. Stellar Capital Management LLC lifted its position in shares of Johnson & Johnson by 2.2% during the second quarter. Stellar Capital Management LLC now owns 30,441 shares of the company’s stock worth $4,281,000 after purchasing an additional 659 shares in the last quarter. Toroso Investments LLC boosted its stake in shares of Johnson & Johnson by 7.8% in the second quarter. Toroso Investments LLC now owns 14,159 shares of the company’s stock valued at $1,991,000 after purchasing an additional 1,028 shares during the period. One Capital Management LLC grew its holdings in shares of Johnson & Johnson by 4.8% in the second quarter. One Capital Management LLC now owns 32,184 shares of the company’s stock valued at $4,526,000 after purchasing an additional 1,461 shares in the last quarter. Finally, Ironwood Investment Management LLC increased its stake in Johnson & Johnson by 3.4% during the 2nd quarter. Ironwood Investment Management LLC now owns 6,787 shares of the company’s stock worth $954,000 after buying an additional 220 shares during the period. Hedge funds and other institutional investors own 67.44% of the company’s stock.

In other news, EVP Ashley Mcevoy sold 29,000 shares of the stock in a transaction dated Tuesday, July 28th. The shares were sold at an average price of $147.47, for a total transaction of $4,276,630.00. Following the completion of the sale, the executive vice president now owns 21,682 shares in the company, valued at $3,197,444.54. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Kathryn E. Wengel sold 16,115 shares of the firm’s stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $153.52, for a total value of $2,473,974.80. Following the transaction, the executive vice president now directly owns 66,658 shares in the company, valued at approximately $10,233,336.16. The disclosure for this sale can be found here. Insiders own 0.27% of the company’s stock.

Several equities analysts have commented on JNJ shares. Bank of America restated a “buy” rating on shares of Johnson & Johnson in a research note on Monday, July 20th. Cantor Fitzgerald restated a “buy” rating and set a $168.00 price target on shares of Johnson & Johnson in a report on Monday, August 3rd. SVB Leerink reaffirmed an “outperform” rating on shares of Johnson & Johnson in a research report on Wednesday, July 15th. Credit Suisse Group reissued a “buy” rating on shares of Johnson & Johnson in a research report on Friday, September 4th. Finally, Stifel Nicolaus cut shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Wednesday, August 19th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and eleven have given a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $163.00.

NYSE JNJ traded up $0.87 during trading hours on Friday, hitting $147.78. The company had a trading volume of 3,933,279 shares, compared to its average volume of 8,528,353. The business has a 50 day moving average of $149.40 and a 200-day moving average of $144.20. The company has a market cap of $394.13 billion, a PE ratio of 21.61, a price-to-earnings-growth ratio of 3.32 and a beta of 0.68. Johnson & Johnson has a 1-year low of $109.16 and a 1-year high of $157.00. The company has a debt-to-equity ratio of 0.40, a quick ratio of 0.99 and a current ratio of 1.25.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Thursday, July 16th. The company reported $1.67 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.50 by $0.17. The business had revenue of $18.34 billion during the quarter, compared to the consensus estimate of $17.73 billion. Johnson & Johnson had a return on equity of 35.21% and a net margin of 22.69%. The business’s quarterly revenue was down 10.8% on a year-over-year basis. During the same period in the previous year, the business earned $2.58 EPS. Sell-side analysts expect that Johnson & Johnson will post 7.85 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 8th. Stockholders of record on Tuesday, August 25th were given a dividend of $1.01 per share. The ex-dividend date was Monday, August 24th. This represents a $4.04 dividend on an annualized basis and a dividend yield of 2.73%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 46.54%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Featured Story: Hedge Funds – How They Work For Investors

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.